Lyra Therapeutics(LYRA)
$0.030.00 (0.00%)
LYRA
Lyra Therapeutics financials statements
$0.03
At close:0.00 (0.00%)
Want to see LYRA full AI Analyst Report?
Lyra Therapeutics (LYRA) Ratios
360 Followers
Lyra Therapeutics Ratios
LYRA's free cash flow for Q4 2025 was $-6.16M. For the 2025 fiscal year, LYRA's free cash flow was decreased by $-96.00K and operating cash flow was $-6.07M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 |
| Quick Ratio | 1.71 | 3.41 | 5.35 | 6.97 | 2.63 |
| Cash Ratio | 1.67 | 3.21 | 1.14 | 2.25 | 2.51 |
| Solvency Ratio | -0.61 | -1.70 | -1.17 | -1.86 | -2.07 |
| Operating Cash Flow Ratio | -3.03 | -5.54 | -3.23 | -3.00 | -1.42 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -30.55M | $ -11.73M | $ 51.64M | $ 71.61M | $ 27.37M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.84 | 0.52 | 0.19 | 0.04 | 0.03 |
| Debt-to-Equity Ratio | -2.82 | 2.97 | 0.30 | 0.05 | 0.04 |
| Debt-to-Capital Ratio | 1.55 | 0.75 | 0.23 | 0.05 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -3.37 | 5.72 | 1.59 | 1.36 | 1.60 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.95 | 0.53 | 0.54 | 0.14 | 0.11 |
| Net Debt to EBITDA | -0.49 | 0.10 | -0.07 | 0.53 | 1.04 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | -10318.95% |
| EBIT Margin | -7425.38% | -3959.13% | -4205.91% | -4034.48% | -15303.51% |
| EBITDA Margin | -7310.05% | -3928.42% | -4188.06% | -3956.20% | -14952.28% |
| Operating Profit Margin | -7794.47% | -6280.83% | -4308.09% | -4131.03% | -15303.51% |
| Pretax Profit Margin | -7263.32% | -6088.40% | -4019.32% | -4054.66% | -15267.72% |
| Net Profit Margin | -7266.08% | -6090.94% | -4023.11% | -4055.61% | -15267.72% |
| Continuous Operations Profit Margin | -7266.08% | -6090.94% | -4023.11% | -4055.61% | -15267.72% |
| Net Income Per EBT | 100.04% | 100.04% | 100.09% | 100.02% | 100.00% |
| EBT Per EBIT | 93.19% | 96.94% | 93.30% | 98.15% | 99.77% |
| Return on Assets (ROA) | -80.09% | -140.83% | -43.96% | -50.27% | -79.31% |
| Return on Equity (ROE) | 269.84% | -805.89% | -70.10% | -68.45% | -126.80% |
| Return on Capital Employed (ROCE) | -116.69% | -179.37% | -54.57% | -58.96% | -119.10% |
| Return on Invested Capital (ROIC) | -98.78% | -166.59% | -52.26% | -56.87% | -115.71% |
| Return on Tangible Assets | -80.09% | -140.83% | -43.96% | -50.27% | -79.31% |
| Earnings Yield | -60.44% | -13.90% | -0.48% | -1.16% | -1.54% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 9.50 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.02 | 0.07 | 0.04 | 0.31 | 0.05 |
| Asset Turnover | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | -38.41 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 38.41 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.86 | -1.08 | -1.27 | -1.43 | -1.99 |
| Free Cash Flow Per Share | -1.87 | -1.11 | -1.29 | -1.44 | -2.25 |
| Dividend Paid and CapEx Coverage Ratio | -248.78 | -29.94 | -60.46 | -264.54 | -7.63 |
| Capital Expenditure Coverage Ratio | -248.78 | -29.94 | -60.46 | -264.54 | -7.63 |
| Operating Cash Flow Coverage Ratio | -0.95 | -2.04 | -2.35 | -10.39 | -17.77 |
| Operating Cash Flow to Sales Ratio | -72.51 | -45.64 | -40.63 | -31.83 | -90.60 |
| Free Cash Flow Yield | -60.56% | -10.77% | -0.49% | -0.92% | -1.03% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.17 | -7.22 | -207.94 | -85.88 | -65.06 |
| Price-to-Sales (P/S) Ratio | 120.22 | 438.05 | 8365.50 | 3482.76 | 9933.23 |
| Price-to-Book (P/B) Ratio | -4.46 | 57.96 | 145.76 | 58.78 | 82.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.65 | -9.29 | -202.54 | -109.00 | -96.93 |
| Price-to-Operating Cash Flow Ratio | -1.66 | -9.60 | -205.89 | -109.42 | -109.64 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.53 | 6.68 | 1.89 | -2.22 |
| Enterprise Value Multiple | -2.14 | -11.05 | -199.82 | -87.51 | -65.39 |
| Enterprise Value | 62.21M | 665.78M | 13.04B | 4.72B | 2.79B |
| EV to EBITDA | -2.14 | -11.05 | -199.82 | -87.51 | -65.39 |
| EV to Sales | 156.31 | 434.01 | 8368.41 | 3461.94 | 9777.81 |
| EV to Free Cash Flow | -2.15 | -9.20 | -202.61 | -108.35 | -95.42 |
| EV to Operating Cash Flow | -2.16 | -9.51 | -205.96 | -108.76 | -107.93 |
| Tangible Book Value Per Share | -0.69 | 0.18 | 1.80 | 2.67 | 2.64 |
| Shareholders’ Equity Per Share | -0.69 | 0.18 | 1.80 | 2.67 | 2.64 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.02 | 0.03 | 0.05 | 0.02 |
| Net Income Per Share | -1.86 | -1.43 | -1.26 | -1.83 | -3.35 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.98 | 1.54 | 0.96 | 1.01 | 1.00 |
| Research & Development to Revenue | 46.26 | 28.53 | 30.83 | 28.46 | 104.19 |
| SG&A to Revenue | 28.99 | 12.06 | 12.23 | 12.88 | 49.85 |
| Stock-Based Compensation to Revenue | 5.87 | 4.38 | 3.78 | 4.00 | 9.72 |
| Income Quality | 1.00 | 0.75 | 1.01 | 0.78 | 0.59 |
Currency in USD

